In a groundbreaking partnership, Dawn Health, a leader in digital health innovation, and global pharmaceutical giant Merck, are collaborating to develop a state-of-the-art digital solution for Growth Hormone Disorders (GHD). Over the next two years, this alliance aims to create a user-centric platform that will significantly enhance the lives of tens of thousands of GHD patients across more than 40 countries.

This initiative leverages cutting-edge AI technologies to incorporate features like growth predictions and advanced personalization into the platform. The potential of AI to transform user experience, boost adoption and adherence, and improve treatment outcomes is a central focus of the project. The solution will cater not only to children and young adults with GHD but also offer invaluable support to their caregivers, both at home and in clinical settings.

Article written by Dawn Health| Image by Unsplash